Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis

Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis

Patients with advanced non-small cell lung cancer (NSCLC) who harbor susceptible epidermal growth factor receptor (EGFR) mutations and are treated with EGFR tyrosine kinase inhibitors (TKIs) show longer progression-free survival (PFS) than those treated with chemotherapy. However, developed EGFR-TKI...

Full description

Bibliographic Details
Main Authors: Tai-Huang Lee, Hsiao-Ling Chen, Hsiu-Mei Chang, Chiou-Mei Wu, Kuan-Li Wu, Chia-Yu Kuo, Po-Ju Wei, Chin-Ling Chen, Hui-Lin Liu, Jen-Yu Hung, Chih-Jen Yang, Inn-Wen Chong
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Journal of Clinical Medicine
Subjects:
epidermal growth factor receptor
EGFR
tyrosine kinase inhibitors
TKIs
bevacizumab
ramucirumab
Online Access:https://www.mdpi.com/2077-0383/11/12/3366

Internet

https://www.mdpi.com/2077-0383/11/12/3366

Similar Items